Dornase alfa and mannitol for cystic fibrosis: analysis of utilisation
Page last updated: 6 March 2015
Drug utilisation sub-committee (DUSC)
October 2014
Abstract
Purpose
To examine the utilisation of dornase alfa and mannitol for cystic fibrosis (CF), including a predicted versus actual (PvA) analysis of mannitol in its first year of listing on the Pharmaceutical Benefits Scheme (PBS). At the February 2014 meeting, the DUSC requested an analysis of mannitol and dornase alfa to be considered at the same meeting as the 24 month PvA of tobramycin inhalation solution.
Date of listing on PBS
- Dornase alfa: 1 February 1996.
- Mannitol: 1 August 2012.
Data Source / methodology
Aggregate data from the DUSC Highly Specialised Drugs Database was used for data relating to packs, prescriptions and expenditure. The Department of Human Services Supplied Prescriptions Database was used for patient number and age.
Key Findings
In the 12 months from May 2013 to April 2014, 1,570 patients received dornase alfa and 106 patients received mannitol on the PBS. The utilisation of mannitol in its first year of listing was lower than expected. The utilisation of dornase alfa has increased steadily since 2004.
